Lilly gains momentum in obesity drug market; controversy over human embryo models heats up

Eli Lilly has shown off data that suggests it could soon have a potent new injectable and a convenient daily pill for weight loss.

June 27, 2023 Check out STAT+

Sponsored By

It's a big day at STAT: Check out our homepage redesign and new shade of teal. And read more about the changes from our executive editor, Rick Berke.

Adobe STAT+ | After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market If its obesity pill and potent new injectable make it to market, Lilly is likely to take market share from Novo drugs like Wegovy. By Elaine Chen STAT+ | Global controversy heats up the race to build human embryo models from stem cells Scientists want to stop saying "synthetic embryos" following controversy over growing stem cells into structures that resemble human embryos. By Megan Molteni For volunteers at an eating disorder hotline, being replaced by an AI chatbot carried a painful cost The National Eating Disorder Association replaced volunteers with an AI chatbot. Volunteers said it came at a personal and professional cost. By Mohana Ravindranath Katy Lemay for STAT STAT+ | With Wegovy and Ozempic's success, can device makers keep up in the race to treat obesity? For the companies developing surgical tools and devices to treat obesity, new drugs present both an opportunity and an existential threat. By Lizzy Lawrence STAT+ | Grail faces uphill battle to get Medicare to cover its cancer screening test Medicare doesn't usually cover tests that screen healthy people, as Grail's cancer screening test Galleri does. By John Wilkerson STAT+ | Lilly reaches $2.4 million settlement with EEOC over age discrimination lawsuit EEOC contended a Lilly executive made a presentation indicating the company's national workforce was "skewed toward the older generation." By Ed Silverman Adobe Opinion: CMS change could slow the crucial growth of 'food as medicine' CMS changes make it harder to deploy food-as-medicine interventions, refine their delivery, and better understand their impact. By Adam Shyevitch

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser